AARD vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 04, 2026

AARD

52.1
AI Score
VS
CBIO Wins

CBIO

58.4
AI Score

Investment Advisor Scores

AARD

52score
Recommendation
HOLD

CBIO

58score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric AARD CBIO Winner
Net Income -35.98M 153,942 CBIO
Operating Income -37.55M -152.63M AARD
ROE -48.1% 0.1% CBIO
ROA -44.2% 0.1% CBIO
Total Assets 81.46M 240.29M CBIO
Cash 73.85M 213.19M CBIO
Current Ratio 12.63 6.56 AARD

Relative Price Performance (Last 90 Days)

AARD 1M: -16.1% · 3M: -16.7% CBIO 1M: -22.8% · 3M: -15.6%

Current Technical Phase

AARD

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.5%), weak momentum, RSI 41

RSI (14): 41.3 · Price: $4.99

CBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 36

RSI (14): 35.6 · Price: $14.32

Fundamentals Snapshot

Metric AARD CBIO
Market Cap — —
Forward P/E -2.1 -5.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin — 1.0%
Operating Margin 0.0% -14.3%
EPS -3.17 -0.14
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CBIO is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.